- Home
- WRAP vs BOLD Comparison
WRAP vs BOLD Comparison
Compare WRAP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRAP | BOLD |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 26.9M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | WRAP | BOLD |
|---|---|---|
| Price | $2.53 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 507.0K | 133.7K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,133,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.20 | $1.00 |
| 52 Week High | $3.00 | $3.12 |
Technical Indicators
Market Signals| Indicator | WRAP | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 54.65 |
| Support Level | $2.09 | $1.15 |
| Resistance Level | $2.62 | $1.24 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.34 | 40.00 |
Price Performance
Historical ComparisonAbout WRAP Wrap Technologies Inc.
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.